HCG Peptide — Human Chorionic Gonadotropin, Lab Use

Human chorionic gonadotropin is not a simple peptide. It is a heterodimeric, glycosylated glycoprotein hormone in the LH/FSH/TSH family. Its molecular identity rests on two associated subunits: a shared alpha subunit and a hormone-specific beta subunit, both carrying carbohydrate groups. That architecture differs fundamentally from a short, single-chain peptide.

A structural crystallography study described a cystine-knot fold and a beta-subunit “seatbelt” stabilising the heterodimer. A structure review placed this subunit arrangement within the wider hormone family. Variable glycosylation means one fixed formula cannot represent every form.

These values define a reference, not a physical sample. Exact mass, glycoform distribution and activity remain batch-linked questions.

Architecture sources: Lapthorn et al. 1994 · PMID 8202136 · Pierce and Parsons 1981 · PMID 6267989

In a rat luteal-tissue receptor-cloning study, LHCGR identified the shared LH/CG receptor and its substantial extracellular ligand-binding domain. In a receptor review, LHCGR connected ligand binding with G-protein signalling. Neither evidence level authenticates supplied material.

In an in-vitro MA-10 mouse Leydig cell model, Clark and colleagues examined StAR-associated cholesterol movement within the tested steroidogenesis system. In an in-vitro immortalised rat granulosa-cell model, Suh and colleagues reported that receptor expression reconstituted hormone-dependent steroidogenesis. These are defined cell-system findings.

Target and pathway sources: McFarland et al. 1989 · PMID 2502842 · Clark et al. 1994 · PMID 7961770 · Suh et al. 1992 · PMID 1328253 · Ascoli et al. 2002 · PMID 11943741

This section describes findings in controlled research and makes no statement about use. Evidence progresses from structural and in-vitro work through preclinical rodent research, analytical measurement and reviews. Each observation remains model- and endpoint-bound; no listed publication analyses a Reborn Peptides batch.

Evidence map: PMID 8202136 · PMID 2502842 · PMID 7961770 · PMID 1328253 · PMID 11145748 · PMID 4673805 · PMID 6267989 · PMID 11943741 · PMID 20735820

Human chorionic gonadotropin, hCG, choriogonadotropin and CG are names for the same molecule. Capitalisation and abbreviation do not create different substances. HCG 5000 IU identifies the catalogue record; batch documents establish supplied characteristics.

International Units express bioassay-standardised potency rather than mass. The unit system uses a WHO standard because variable glycosylation can affect activity, so equal masses need not represent equivalent potency. A catalogue IU designation is not interchangeable with milligrams and does not prove batch activity.

hCG is distinct from Kisspeptin-10, Tesamorelin and Ipamorelin. Kisspeptin-10 is a sequence-defined peptide investigated through KISS1R, whereas Tesamorelin and Ipamorelin are catalogued in connection with the GH axis. Their identifiers, analytical expectations and research findings cannot be transferred to this glycosylated heterodimer.

Urine-derived and recombinant material are possible source variants, but neither is asserted here. Source, glycoform distribution and comparability belong in the applicable specification and batch documentation.

Naming and molecular-form context: Pierce and Parsons 1981 · PMID 6267989 · Cole 2010 · PMID 20735820

No physical presentation, fill quantity, source variant, storage condition or stability period is asserted here. Those particulars must come from the released label, applicable specification and matching batch documentation. The catalogue designation and literature reference values do not establish them.

The product designation, batch code, test date, analytical method and result should form a traceable chain across label, specification and COA. Exact mass, glycoform information and IU-specific activity belong within that released record.

Any HPLC purity value applies only to the tested batch and stated method. It does not by itself establish biological potency, complete glycoform identity or equivalence between source variants. Chromatography, molecular identity and bioassay-standardised potency answer separate analytical questions.

Laboratories evaluating HCG 5000 IU research supply in the EU should separate published from batch evidence. Papers define investigated structures, models and endpoints; released documents define a supplied sample.

HCG 5000 IU is presented solely as research material for controlled laboratory work. No listed publication certifies Reborn Peptides material, and no catalogue statement replaces batch-specific analytical review.

Research use only. For laboratory research only. Not for human or veterinary use. Not intended to diagnose, treat, cure or prevent any disease. Not a medicinal product, food or cosmetic.